BOTOX 200 Allergan Units Powder for Solution for Injection

BOTOX

Botulinum toxin (neurotoxin) injectable – prescription-only medicine

Aesthetic neuromodulator and therapeutic botulinum toxin type A, 200 Unit vial

Authorised in the UK as a prescription Only medicine (POM) with a Summary of Product Characteristics (SmPC) for BOTOX 200 Allergan Units Powder for solution for injection.
Regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA) under the Human Medicines Regulations for quality, safety and efficacy.
Complies with EU and UK requirements for biological medicinal products, including Good Manufacturing Practice (GMP) and pharmacovigilance obligations.
Supported by European regulatory documentation and oversight (historic approvals via EMA and national competent authorities) for multiple therapeutic and aesthetic indications.
Subject to FDA and other international regulatory approvals as onabotulinumtoxinA for numerous labelled indications, with product monographs and boxed warnings describing safety considerations.

Authorised in the UK as a prescription Only medicine (POM) with a Summary of Product Characteristics (SmPC) for BOTOX 200 Allergan Units Powder for solution for injection.
Regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA) under the Human Medicines Regulations for quality, safety and efficacy.
Complies with EU and UK requirements for biological medicinal products, including Good Manufacturing Practice (GMP) and pharmacovigilance obligations.
Supported by European regulatory documentation and oversight (historic approvals via EMA and national competent authorities) for multiple therapeutic and aesthetic indications.
Subject to FDA and other international regulatory approvals as onabotulinumtoxinA for numerous labelled indications, with product monographs and boxed warnings describing safety considerations.

Aesthetic neuromodulator and therapeutic botulinum toxin type A, 200 Unit vial

Description

BOTOX 200 Allergan Units is a highly purified botulinum toxin type A (onabotulinumtoxinA) powder for solution for injection, supplied as a single 200-Unit vial for reconstitution with sterile sodium chloride. Developed by Allergan and now marketed by AbbVie, BOTOX is a prescription-only neuromodulator used worldwide for both aesthetic and therapeutic indications. It acts at the neuromuscular junction by blocking the release of acetylcholine, thereby producing a reversible chemical denervation of the injected muscles or glands. Clinically, this results in relaxation of overactive muscles, reduction of muscle spasticity or dystonia, smoothing of dynamic facial lines such as glabellar frown lines, crow’s feet and horizontal forehead lines, and reduction of glandular secretion in conditions such as severe primary axillary hyperhidrosis and certain bladder dysfunctions. BOTOX has an extensive clinical evidence base and a long-established safety profile when used by appropriately trained healthcare professionals, with effects typically lasting several months and dosing tailored to each licensed indication.

Bnefits

Gold-standard, globally recognised brand of botulinum toxin type A with decades of clinical use and extensive safety and efficacy data.
Provides predictable, reversible neuromuscular blockade that smooths dynamic facial wrinkles and treats multiple neurologic, bladder and autonomic conditions.
Highly purified botulinum toxin type A with precisely defined Allergan Units; doses are indication-specific and non-interchangeable with other toxin preparations.
Allows targeted treatment of glabellar lines, crow’s feet, horizontal forehead lines and platysma bands for natural-looking facial rejuvenation when correctly dosed.
Licensed for a wide range of therapeutic indications including focal spasticity, cervical dystonia, blepharospasm, chronic migraine, overactive bladder, neurogenic detrusor overactivity and severe primary axillary hyperhidrosis.
Long duration of effect: clinical benefit usually begins within a few days, peaks by around 1–2 weeks and commonly lasts about 3–6 months depending on the indication and dose.
Enables dose titration and individualised treatment plans with defined maximum cumulative doses per 12-week interval to optimise benefit–risk balance.
Supplied as a sterile powder for solution in a single-use glass vial, with clear guidance on reconstitution, dilution, injection technique and storage.
Backed by comprehensive regulatory documentation (SmPC, PIL, product monographs) and ongoing pharmacovigilance from global regulatory agencies.
Widely available in specialist aesthetic clinics, neurology, rehabilitation, dermatology, urology and pain services, supporting consistent standards of care.

Indications

Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows (glabellar lines) seen at maximum frown in adults when the severity has an important psychological impact.
Temporary improvement in the appearance of moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile in adults when the severity has an important psychological impact.
Temporary improvement in the appearance of moderate to severe horizontal forehead lines seen at maximum eyebrow elevation in adults when the severity has an important psychological impact (often in combination with glabellar line treatment).
Temporary improvement in the appearance of moderate to severe platysma prominence (platysmal bands) at maximum contraction in adults when the severity has an important psychological impact.
Symptomatic treatment of focal spasticity affecting elbow, wrist and hand muscles in paediatric cerebral palsy patients aged 2 years and older as an adjunct to rehabilitative therapy.
Symptomatic treatment of focal spasticity affecting the ankle and foot in ambulant paediatric cerebral palsy patients aged 2 years and older as an adjunct to rehabilitative therapy.
Symptomatic treatment of upper limb spasticity in adults.
Symptomatic treatment of ankle and foot disability due to lower limb spasticity in adults.
Symptomatic relief of blepharospasm and hemifacial spasm.
Symptomatic treatment of idiopathic cervical dystonia (spasmodic torticollis).
Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).
Management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics, including overactive bladder with symptoms of urinary incontinence, urgency and frequency.
Management of neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis.
Management of severe primary hyperhidrosis of the axillae that does not respond to topical treatment with antiperspirants or antihidrotics.
Offered in aesthetics practice (off-label in some jurisdictions) for additional dynamic facial lines and bruxism where permitted and performed by appropriately trained professionals, following local regulations.

Composition

Active ingredient: Botulinum toxin type A (onabotulinumtoxinA) 200 Allergan Units per vial, produced from Clostridium botulinum.
Excipients: Human albumin.
Excipients: Sodium chloride.
Powder appears as a thin white deposit on the base of the clear glass vial prior to reconstitution.

Formulation

Pharmaceutical form: Powder for solution for injection.
Sterile, vacuum-dried, purified botulinum toxin type A supplied in a single-use clear glass vial with rubber stopper and tamper-proof aluminium seal.
Reconstituted immediately before use with sterile, unpreserved 0.9% sodium chloride solution for injection according to the dilution tables provided in the SmPC.
Reconstituted solution is a clear, colourless to slightly yellow solution free of particulate matter, intended for intramuscular, intradermal or intradetrusor injection depending on the indication.

Packaging

Carton containing one 200 Allergan Unit glass vial of BOTOX and the accompanying package leaflet (PIL).
Vial: clear glass with rubber stopper and tamper-proof aluminium seal, containing white powder for solution for injection.
Pack sizes authorised may include cartons containing one, two, three or six 200-Unit vials, although not all pack sizes are marketed in every country.
AestheticsRX Pharma listing: each package supplied as 1 vial containing 200 Units of botulinum toxin type A, intended for single use after reconstitution.

Usage

BOTOX is a prescription-only medicine and must only be administered by appropriately qualified healthcare practitioners experienced in the treatment of the relevant indication and in the use of botulinum toxin type A.
Reconstitute each vial strictly according to the SmPC using sterile, unpreserved 0.9% sodium chloride solution for injection, taking care to inject diluent gently into the vial to avoid denaturation (no vigorous shaking or bubbling).
Use the specific dilution volumes recommended for the 200-Unit presentation to achieve the desired concentration in Units per 0.1 ml for each indication; label syringes clearly with the concentration.
Inspect the reconstituted solution to ensure that it is clear and free of particulate matter before use; discard the vial if the solution is discoloured or particles are present, or if a vacuum does not draw diluent into the vial upon reconstitution.
Administer by slow injection into the appropriate anatomical sites according to indication: intramuscular injection into targeted muscles for spasticity, dystonia and most aesthetic uses; intradermal injection into affected axillary areas for severe primary hyperhidrosis; intradetrusor injection via cystoscope for overactive bladder and neurogenic detrusor overactivity.
For facial aesthetic indications, inject small volumes into the specific muscles responsible for glabellar lines, crow’s feet and forehead lines while respecting recommended maximum doses and injection patterns to minimise adverse effects such as ptosis or asymmetry.
For chronic migraine, bladder disorders, focal spasticity and other therapeutic uses, follow indication-specific dosing regimens, injection maps and maximum total doses as detailed in the SmPC or local clinical guidelines.
Do not exceed a cumulative dose of 400 Units in any 12-week interval in adults, including when treating multiple indications; in paediatric patients, adhere to bodyweight-based limits and the lower of 10 Units/kg or 340 Units in a 12-week interval where applicable.
Clinical improvement generally begins within the first few days after injection, with maximum effect around 1–2 weeks; repeat treatment should be considered only when the effect of the previous injection has worn off and not more frequently than every 12 weeks.
Use appropriate aseptic technique, needle size and guidance methods (e.g. EMG, ultrasound or nerve stimulation for certain spasticity indications) and dispose of all used vials, needles and syringes as clinical sharps according to local regulations.

Contraindications

Known hypersensitivity to botulinum toxin type A or to any of the excipients (human albumin or sodium chloride).
Presence of infection at the proposed injection site(s).
For bladder indications, the presence of urinary tract infection at the time of treatment, acute urinary retention in patients who are not routinely catheterising, patients unwilling or unable to initiate catheterisation if required post-treatment, or the presence of bladder calculi.
Patients with generalised disorders of muscle activity or significant neuromuscular junction disorders (e.g. myasthenia gravis, Lambert–Eaton myasthenic syndrome, amyotrophic lateral sclerosis and similar conditions) where there is increased risk of systemic weakness.
Patients with pre-existing swallowing or breathing difficulties where further weakening of oropharyngeal or respiratory muscles could pose significant risk, unless the potential benefit clearly outweighs the risk and appropriate monitoring is available.
Use in pregnant women is not recommended; BOTOX should be avoided during pregnancy unless clearly necessary based on the prescriber’s benefit–risk assessment.
Use in breastfeeding women is generally not recommended because it is unknown whether botulinum toxin type A is excreted in human milk.
Use in patients with significant bleeding disorders or on anticoagulant therapy may require special caution or avoidance of certain injection sites due to increased bleeding risk at injection sites.
Concomitant use with certain aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission may potentiate the effect of botulinum toxin; use with caution or avoid where clinically appropriate.
Use by untrained personnel or outside an appropriate clinical setting; BOTOX is not intended for self-administration.

Adverse Effects

Local injection-site reactions such as pain, tenderness, bruising, erythema, swelling and mild bleeding.
Localized muscle weakness near the injection site, which may manifest as brow or eyelid ptosis, asymmetry, difficulty in fully closing the eye, altered facial expression or changes in smile depending on injection pattern.
Headache and flu-like symptoms (e.g. fatigue, malaise, myalgia, mild fever) following treatment, particularly in aesthetic facial indications and chronic migraine.
Dry eye, tearing abnormalities, blurred vision, diplopia or eye irritation with periocular injections (e.g. for blepharospasm or crow’s feet), and rarely corneal exposure complications if eyelid closure is affected.
Dysphagia (difficulty swallowing), dysphonia, neck weakness and dry mouth, particularly in cervical dystonia treatment, which can occasionally be severe and require medical intervention.
Generalised muscle weakness, asthenia or falls in susceptible patients, especially if doses are high or multiple muscle groups are treated.
For hyperhidrosis treatment, compensatory sweating in other body areas, injection-site pain and mild local sensory changes.
For bladder indications, urinary tract infection, urinary retention, dysuria and, in patients with neurologic disease, episodes of autonomic dysreflexia that may require prompt medical management.
Hypersensitivity reactions including rash, pruritus, urticaria, soft-tissue oedema and, very rarely, anaphylaxis; emergency treatment for anaphylactic reactions should be readily available.
Very rare reports of distant spread of toxin effect leading to symptoms such as generalized muscle weakness, ptosis, diplopia, dysphagia, dysarthria, respiratory difficulty or aspiration pneumonia; such events may be serious and warrant urgent medical attention.
Development of neutralising antibodies in a small subset of patients with repeated high-dose or frequent treatments, potentially reducing clinical response over time.

Storage Conditions

Store unopened vials in a refrigerator at 2°C–8°C or in a freezer at -5°C to -20°C, in accordance with the storage conditions specified in the SmPC.
Keep vials in the outer carton to protect them from light and maintain correct temperature control throughout storage and transport (cold-chain conditions as per local requirements).
Shelf life of unopened vials is typically 3 years when stored within the specified temperature range; do not use beyond the expiry date printed on the carton and vial.
After reconstitution with sterile 0.9% sodium chloride solution, chemical and physical stability has been demonstrated for up to 24 hours when stored at 2°C–8°C; however, from a microbiological standpoint, the product should be used immediately after reconstitution wherever possible.
If reconstituted solution is not used immediately, the in-use storage time and conditions prior to administration should not normally exceed 24 hours at 2°C–8°C, and responsibility for these conditions lies with the user.
Reconstituted solution should be stored in a refrigerator (2°C–8°C) if not used immediately and discarded after 24 hours; any unused solution or partially used vials must be disposed of appropriately and must not be frozen or reused.
Keep out of the sight and reach of children, and dispose of unused product, reconstituted solution, spillage and contaminated materials in accordance with local requirements for cytotoxic or biologically active medicinal products.

Duration

For most indications, a single treatment session provides clinical benefit for approximately 3\u20136 months. In facial aesthetics (glabellar, crow\u2019s feet and forehead lines), visible effects usually last around 3\u20134 months before muscle activity gradually returns. In some therapeutic indications such as chronic migraine, spasticity or bladder disorders, median response durations of several months (often around 12\u201324 weeks or longer for certain bladder indications) are reported, after which re-injection may be considered, typically not sooner than 12 weeks after the previous treatment.

Onset

Initial improvements typically appear within 3\u20135 days after injection, with maximum clinical effect usually observed around 1\u20132 weeks post-treatment. For some therapeutic indications, full benefit may evolve over several weeks. The onset and magnitude of effect depend on the dose, injection technique, treated muscles or glands and the individual patient\u2019s response.